Abstracts

Citation

Ceejay L. Boyce, Marley D. Bishop, Sheila M. Styrchak, Kevin Knowles, Cindy Vavro, Rohan Hazra, Ellen Townley, Robert Nixon, Robert A. Smith, Geoffrey S. Gottlieb, Theodore D. Ruel, Andrew A. Wiznia, Lisa M. Frenkel, IMPAACT P1093 Team. Prevalence and dynamics of drug resistance during dolutegravir-containing treatment in a pediatric population living with HIV-1 (IMPAACT P1093). Presented at: IAS 2023.

Citation

T Ruel, E Acosta, R Singh, C Alvero, T Fenton, K George, S Popson, E Townley, R Hazra, C Brothers, C Vavro, A Buchanan, A Wiznia, IMPAACT P1093 team. Pharmacokinetic and 4-week safety/efficacy of dolutegravir (S/GSK1349572) dispersible tablets in HIV-infected children aged 4 weeks to 6 years: Results from IMPAACT P1093. Presented at: IAS 2018.

Citation

Cindy Vavro, Ted Ruel, Andrew Wiznia, Carmelita Alvero, Stephanie Popson, Terry Fenton, Rohan Hazra, Ellen Townley, Ann Buchanan, Paul Palumbo. Emergence of Resistance in HIV-1 Integrase (IN) Following Dolutegravir (DTG) Treatment in 6 to 18 Year Old Participants Enrolled in the P1093 Study. Presented at: IAS 2018.

Citation

Cindy Vavro, Paul Palumbo, Andrew Wiznia, Carmelita Alvero, Bobbie Graham, Terry Fenton, Rohan Hazra, Ellen O’Gara, Ann M Buchanan, Joe Horton, Rolando M Viani. Evolution of HIV-1 Integrase Following Selection of R263K with Further Dolutegravir Treatment; A Case Report from the P1093 study. Presented at: IAS 2015.

Citation

Michael McKenna, Zrinka Lulic, Ann M. Buchanan, Cynthia Brothers, Lionel Tan, Marcia Wang, Sean Brummel, Lauren Ziemba, Theodore Ruel, Patricia M. Flynn, Helena Rabie, Andrew Wiznia. Dolutegravir and Growth in Pediatric Populations With HIV-1: IMPAACT P1093 and IMPAACT 2019. Presented at: CROI 2024.

Citation

Safety and Efficacy of Dolutegravir (DTG; GSK1349572) in Treatment-Experienced HIV-1 Infected Adolescents: 24-Week Results from IMPAACT P1093.

Citation

Ceejay Boyce. Prevalence and dynamics of drug resistance during dolutegravir-containing treatment in a pediatric population living with HIV-1 (IMPAACT P1093). Presented at: IAS 2023; 2023 Jul 26.

Citation

T Ruel, E Acosta, R Singh, C Alvero, K George, S Popson, M Bartlett, A Buchanan, C Brothers, L Koech, T Vhembo, R Hazra, E Townley, A Wiznia, P1093 team. PK and 4-week outcomes of dolutegravir dispersible tablets in HIV-infected children. Presented at: CROI 2019; 2019 Mar 07.

Citation

Andrew Wiznia, Carmelita Alvero, Terry Fenton, Kathleen George, Ellen Townley, Rohan Hazra, Barb Heckman, Annie Buchannan, Cindy Vavro, Rolando Viani on behalf of the P1093 study team. IMPAACT 1093: Dolutegravir in 6-12 Year Old HIV Infected Children: 48-Week Results. Presented at: CROI 2016; 2016 Feb 23.

Citation

Pharmacokinetics, Safety, and Efficacy of Dolutegravir (DTG; S/GSK1349572) in HIV-1 Infected Adolescents: Preliminary analysis from IMPAACT 1093. Presented at: XIX International AIDS Conference.